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Background: Antimicrobial stewardship has been promoted as a key strategy for coping with the problems of
antimicrobial resistance and Clostridium difficile. Despite the current call for stewardship in community hospitals,
including smaller community hospitals, practical examples of stewardship programs are scarce in the reported
literature. The purpose of the current report is to describe the implementation of an antimicrobial stewardship
program on the medical-surgical service of a 100-bed community hospital employing a core strategy of
post-prescriptive audit with intervention and feedback.
Methods: For one hour twice weekly, an infectious diseases physician and a clinical pharmacist audited medical
records of inpatients receiving systemic antimicrobial therapy and made non-binding, written recommendations
that were subsequently scored for implementation. Defined daily doses (DDDs; World Health Organization Center
for Drug Statistics Methodology) and acquisition costs per admission and per patient-day were calculated monthly
for all administered antimicrobial agents.
Results: The antimicrobial stewardship team (AST) made one or more recommendations for 313 of 367 audits
during a 16-month intervention period (September 2009 – December 2010). Physicians implemented
recommendation(s) from each of 234 (75%) audits, including from 85 of 115 for which discontinuation of all
antimicrobial therapy was recommended. In comparison to an 8-month baseline period (January 2009 – August
2009), there was a 22% decrease in defined daily doses per 100 admissions (P = .006) and a 16% reduction per
1000 patient-days (P = .013). There was a 32% reduction in antimicrobial acquisition cost per admission (P = .013)
and a 25% acquisition cost reduction per patient-day (P = .022).
Conclusions: An effective antimicrobial stewardship program was implemented with limited resources on the
medical-surgical service of a 100-bed community hospital.
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Hospitals with less than 200 beds accounted for 72% of
American Hospital Association-defined community hos-
pitals in 2008 and 63% of the acute care facilities report-
ing to the National Healthcare Safety Network (NHSN)
in 2010 [1,2]. Recent reports have demonstrated that
large and small hospitals alike comparably share the
problem of antimicrobial resistance. An analysis of data* Correspondence: storeydf@gmail.com
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reproduction in any medium, provided the orfrom the National Nosocomial Infection Surveillance
(NNIS) System demonstrated parallel increases in anti-
microbial resistance in Staphylococcus aureus blood
stream infections, Escherichia coli urinary tract infec-
tions and Pseudomonas aeruginosa pneumonias within
large and small acute-care facilities between the periods
of 1990–1994 and 2000–2004 [3]. In addition, intensive
care units of small and large hospitals reporting to
NHSN were shown to have comparable proportions of
device-associated infections with multidrug-resistant
Klebsiella pneumoniae and E. coli [4]. Similarly, the pro-
portion of Acinetobacter baumannii that was multidrug-Ltd. This is an Open Access article distributed under the terms of the Creative
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compared to larger, tertiary facilities. Furthermore, smal-
ler bed size was independently associated with a higher
rate of incident Clostridium difficile infection (CDI)
cases reported among 210 Ohio acute care hospitals dur-
ing 2006 [5].
Antimicrobial stewardship has been promoted for all
hospitals to help cope with the challenges of CDI and
emerging resistance to antibiotics [6-8]. In 2007, the Infec-
tious Diseases Society of America (IDSA) and the Society
for Healthcare Epidemiology of America (SHEA) pub-
lished revised guidelines for developing institutional pro-
grams to enhance antimicrobial stewardship [9]. Several
recent surveys have suggested antimicrobial stewardship
programs (ASPs) may be more prevalent than appreciated
from a review of the medical literature [10,11]. Neverthe-
less, a 2011 report of a survey of infectious diseases (ID)
specialists of the IDSA Emerging Infections Network con-
cludes that “small community hospitals still represent the
‘frontier’ for new stewardship programs” and that they are
the hospitals “least likely to have ASPs, the least likely to
provide compensation to physicians, and the least likely to
believe that any outcomes data might convince adminis-
trators to support ASPs” [12]. Even so, smaller hospitals
may have higher rates of antimicrobial use than those of
large academic medical centers [13]. It has been nearly a
decade since the only report of an ASP from a community
hospital in the United States with less than 200 beds [14].
We report the implementation of a contemporary ASP on




An ASP was implemented on the medical-surgical ser-
vice of a full-service 100-bed community hospital
located in an ethnically diverse community in metropol-
itan Dallas, TX. The 43-bed medical-surgical service
consisted of a 24-bed medical-surgical floor unit, 11-bed
progressive care unit, and 8-bed medical-surgical inten-
sive care unit. There were no inpatient transplant ser-
vices, specialized oncology, pediatric, psychiatric, or
rehabilitation units. Medical subspecialties were broadly
represented and included infectious diseases (ID); surgi-
cal specialties included cardiothoracic surgery, colorectal
surgery, general surgery, neurosurgery and orthopedic
surgery. An electronic medical record was available but
without computerized physician order entry or elec-
tronic progress notes.
Throughout the reported period, a nurse staffed an in-
fection prevention and control program that included
surveillance and prevention activities for multidrug-
resistant organisms, CDI, and device-associated infec-
tions. Since 2006 and throughout the reported period,an ID physician served as the medical director of infec-
tion control and employee health. Active admission sur-
veillance testing for methicillin-resistant Staphylococcus
aureus was performed on high-risk patients for isolation
and cohorting purposes. An off-site laboratory per-
formed microbiology services including preparation of
an annual facility antibiogram and polymerase chain re-
action testing for CDI. (Laboratory testing for CDI was
performed on-site using an enzyme-linked immunoassay
for C. difficile toxin prior to November 2009).
The pharmacy was staffed by 6.4 full-time-equivalent
pharmacists, including a pharmacy director and clinical
pharmacy supervisor. The pharmacists did not receive
specialized training in infectious diseases.
Interventions
During the baseline period (January 2009 – August
2009), the ID physician medical director of infection
control, the clinical pharmacy supervisor and the phar-
macy director together formed an Antimicrobial Stew-
ardship Team (AST) and drafted an antimicrobial
stewardship policy and program description for approval
by the Pharmacy and Therapeutics Committee and Med-
ical Executive Committee. AST members educated the
medical staff about the program through presentations
at medical staff committee meetings and through a con-
tinuing medical education conference. For approximately
one hour twice weekly during the intervention period
(September 2009 – December 2010), the ID physician
and one or the other of the AST pharmacists audited
medical records of inpatients on the medical-surgical ser-
vice that were receiving more than two days of systemic
antimicrobial therapy. On occasion, the AST audited
other patient records with shorter durations of therapy.
The AST members audited records for prescribed anti-
microbial agent(s), clinical indication(s), planned treat-
ment duration(s), drug allergies, renal function, pertinent
laboratory and radiographic data. Non-binding written
recommendations were made and placed in the record
using a communication form that did not become part of
the permanent medical record. There were no formulary
restrictions or preauthorization requirements.
Additional interventions implemented prior to the
baseline period included automatic vancomycin dose-
optimization and a pneumonia order set. Order sets for
treating patients with severe sepsis or, suspected severe
sepsis, and a parenteral to oral conversion protocol were
implemented during the intervention period. A timeline
with ASP milestones and interventions is displayed in
Figure 1.
Data collection
The AST categorized recommendations as follows: to
discontinue all agent(s), to de-escalate antimicrobial
' 09 Jan 2009 Mar May Jul Sep Nov 
Jan 
2010 
Mar May Jul Sep Nov ' 10 
Intervention Period Ends Intervention Period Begins 
Baseline Period Ends Baseline Period Begins 
Pneumonia order set 
Vancomycin dose-optimization protocol 
Severe sepsis order sets 
Parenteral to oral conversion protocol 
Figure 1 Antimicrobial stewardship program implementation timeline. The timeline depicts antimicrobial stewardship program milestones
and interventions. A pneumonia order set and vancomycin dose-optimization protocol were implemented prior to the baseline period. Severe
sepsis order sets and a parenteral to oral conversion protocol were implemented during the intervention period. The severe sepsis order sets
included choices for initial antibiotic regimen by suspected source of infection and a schedule for continued therapy without automatic stop
orders or requirements for physician justification. Individual agents included in the order sets were ampicillin, ampicillin-sulbactam, azithromycin,
aztreonam, ceftriaxone, levofloxacin, linezolid, meropenem, piperacillin-tazobactam, rifampin and vancomycin. Antimicrobial agents in the
parenteral to oral conversion protocol were fluconazole, levofloxacin, linezolid, metronidazole and voriconazole at the same dose and frequency.
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stitute an alternate agent(s) with decreased spectrum of
activity), to limit duration, to broaden coverage (to add
one or more agents and/or substitute alternate agents(s)
with increased spectrum of activity), to optimize dose
(e.g., for indication, renal function, and/or body weight),
to convert route of administration from parenteral to oral
and to consult ID. Pharmacist team members followed
up recommendations and scored implementation. Data
from record review and recommendations were tabu-
lated monthly.
Admissions, patient-days (excluding outpatient-days),
Medicare Case Mix Index, and characteristics of patients
discharged from the medical-surgical service were
obtained from hospital administrative databases. Facility-
wide acquisition and/or return costs and quantities for
all systemic antimicrobial agents (antibacterial, antifun-
gal and antiviral) were recorded monthly from pharmacy
records for the baseline and intervention periods. In
addition, administered quantities of antimicrobials were
recorded monthly for each patient care location of the
medical-surgical service and defined daily doses (DDDs;
World Health Organization Center for Drug Statistics
Methodology) were calculated. Antimicrobial acquisition
costs were estimated by multiplying administered anti-
microbial unit quantities by the 2009–2010 facility
average acquisition price per unit. Incident healthcare-
facility-onset CDI cases were scored and incidence rates
calculated per 10,000 patient-days according to theNHSN multidrug-resistant organism and CDI module
protocol laboratory-identified event methodology [15].
Statistical analysis
Patient characteristics, antimicrobial use and cost, and
CDI rates were compared during baseline and interven-
tion periods. The Mann–Whitney U test was used for
continuous variable distributions, and the χ
2 test was used
for categorical variables. All reported P values were two-
tailed with P less than .05 as the level of significance.




There were 1,422 admissions and 5,572 patient-days on
the medical-surgical service during the 8-month baseline
period and 3,076 admissions and 11,109 patient-days
during the 16-month intervention period. Patient char-
acteristics of the medical-surgical service are summar-
ized in Table 1. Primary diagnoses were similar between
the two periods except for diseases of the circulatory
system (P = .027). The mean monthly, facility-wide
Medicare Case Mix Index increased from 1.4 to 1.6, or
by 14% (P = .005).
There were 367 audits of 333 unique inpatient records
during the stewardship period (Table 2). At the time of
audit, 349 (95%) patients had been prescribed antimicro-
bial therapy for three or more consecutive days, 168
Table 1 Patient characteristics during baseline and
intervention periods of an antimicrobial stewardship
program
Variable Baseline Intervention Pa
Discharges, no. 1409 3054
Age, mean (SD), years 57.4 (18.6) 57.4 (18.7) .933
Male sex 628 (44.6) 1304 (42.7) .241
Race
Asian 93 (6.6) 197 (6.5) .850
Black 185 (13.1) 463 (15.2) .074
Hispanic 180 (12.8) 377 (12.3) .686
White 940 (66.7) 1971 (64.5) .156
Health insurance
Commercial, HMO, PPO 627 (44.5) 1274 (41.7) .084
Medicare, Managed Care Medicare 639 (45.4) 1382 (45.3) .951
Medicaid, Managed Care Medicaid 37 (2.6) 95 (3.1) .374
ALOS, mean (SD), days 3.9 (0.3) 3.6 (0.3) .118
Primary ICD-9 diagnosis code(s)
Circulatory 314 (22.3) 593 (19.4) .027
Diabetes mellitus 19 (1.3) 48 (1.6) .569
Digestive 202 (14.3) 468 (15.3) .391
Genitourinary 182 (12.9) 454 (14.9) .083
Infectious and parasitic 57 (4.0) 110 (3.6) .468
Musculoskeletal and connective tissue 61 (4.3) 160 (5.2) .193
Neoplasms 144 (10.2) 293 (9.6) .513
Respiratory 124 (8.8) 276 (9.0) .797
Skin and subcutaneous tissue 43 (3.1) 81 (2.7) .450
NOTE:
Data are no. (%) of discharged medical-surgical service patients, unless
otherwise indicated.
a - The Mann–Whitney U test was used to compare continuous data, and the
χ2 test was used to compare categorical data.
Abbreviations: ALOS, average length of stay; HMO, health maintenance
organization; ICD-9, International Classification of Diseases, 9th Revision; PPO,
preferred provider organization; SD, standard deviation.
Table 2 Characteristics of antimicrobial prescription








Parenteral agent(s) part of regimen 336 (91.6)
Fluoroquinolonea part of regimen 206 (56.1)





Skin and soft tissue 46 (12.5)
Other 25 (6.8)
NOTE:
a - Levofloxacin was the only fluoroquinolone prescribed among the audited
records.
b - Amoxicillin-clavulanate, ampicillin-sulbactam, clindamycin, ertapenem,
imipenem, meropenem, metronidazole and piperacillin-tazobactam.
c - Patients were allowed more than one indication per record audit.
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were receiving fluoroquinolones (levofloxacin) and 13
(4%) were receiving two agents with anaerobic activity.
Suspected or confirmed pulmonary infection was a ra-
tionale for antimicrobial therapy in 173 (47%) audits and
the most common indication for prescribed antimicro-
bial therapy.
Characteristics of AST recommendations are summar-
ized in Table 3. The AST advised no change to the pre-
scribed antimicrobial regimen for 54 audits and made
one or more recommendation(s) to change the pre-
scribed antimicrobial regimen (or consult ID) for 313
audits during the stewardship period. Physicians imple-
mented recommendation(s) from each of 234 (75%)
audits, including from 85 of 115 for which discontinu-
ation of all antimicrobial therapy was recommended.Antimicrobial use and cost, and CDI
There was a 22% reduction in mean monthly use of all
antimicrobial agents per 100 admissions (P = .006) and a
32% reduction in cost per admission (P = .013) in com-
parison to the baseline period (Table 4). Antimicrobial
use and cost were also calculated per patient-day. There
was a 16% reduction in mean monthly antimicrobial use
per 1000 patient-days (P = .013) and a 25% reduction in
cost per patient-day (P = .022). There were statistically
significant reductions from baseline in the use of anti-
pseudomonal carbapenems (imipenem and meropenem),
clindamycin, levofloxacin, linezolid, trimethroprim-sulfa-
methoxazole, antibacterials and antifungals using either
metric denominator; there was a statistically significant
increase from baseline in the use of cefazolin.
The mean monthly, incident healthcare-facility-onset
CDI incidence rate for the medical-surgical service was
3.7 during the baseline period and 9.2 during the inter-
vention period (P = .232).
Discussion
In summary, we report the implementation of an ASP at
a 100-bed community hospital employing a core strategy
of post-prescriptive medical record audits and nonbind-
ing AST recommendations with significant reductions in
antimicrobial use and cost.
Respondents to a 2009 survey of the IDSA Emerging
Infections Network on programmatic strategies and














De-escalatea 65 53 82




Optimize dose 14 7 50








a - Discontinuation of one or more agent(s) and/or substitution of alternate
agent(s) with decreased spectrum of activity.
b - Limit duration for same agent(s) at same dose, route and schedule.
c - Addition of one or more agent(s) and/or substitution of alternate agent(s)
with increased spectrum of activity.
d - Parenteral to oral conversion(s) of same agent(s) at same dose and
schedule.
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their hospitals had an ASP and that 12% were planning
to initiate one [12]. However, respondents from hospitals
with less than 200 beds reported that only 44% of their
hospitals had an existing ASP; even so, the survey was
thought to “likely overestimate the dissemination of
ASPs”. Lack of funding and/or personnel were consid-
ered to be primary barriers to ASP implementation.
Additional challenges in the implementation of our
program included data management and the creation of
data management tools, program documents, proce-
dures, and reports as well as educational materials for
the medical staff.
Although other reports have been published about
ASPs implemented in community hospitals [16,17], only
one has previously described an ASP at a facility in the
United States with less than 200 beds. In 2003, LaRocco
described an antibiotic support team developed at a 120-
bed facility in Louisiana [14]. Concurrent chart review
was performed three days per week focusing on multiple,
prolonged and high-cost antibiotic therapies. There was
a 19% savings on antibiotic costs per patient-day over a
12-month intervention period. We employed a similar
core strategy but with a 2-person ID physician/clinical
pharmacist team that audited medical records two days
per week. We limited our audits to patients on the
medical-surgical service, as others have reported [18],
and demonstrated a 25% cost reduction per patient-day
(P = .022). LaRocco did not report use metrics; there
may be other unknown differences in the setting, patientcharacteristics, interventions, and data analysis limiting
any further comparisons between these two programs.
The generation of recommended antimicrobial use
metrics was among our greatest challenges. We selected
DDD as recommended by the IDSA/SHEA stewardship
guidelines [9]. Days of therapy were not available from
pharmacy records. These same stewardship guidelines
are silent on the recommendation for a metric denomin-
ator(s); we calculated both DDD per admission and per
patient day, as recommended by others [19-21].
There were few differences in patient characteristics
between the baseline and intervention periods. The
facility-wide Medicare Case Mix Index increased signifi-
cantly during the intervention period; however it is un-
clear how this may be related to antimicrobial use on
the medical-surgical service.
Severe sepsis order sets and a parenteral to oral con-
version protocol were implemented during the interven-
tion period. The order sets did not limit duration of
antimicrobial therapy and the parenteral to oral conver-
sion protocol included only five antimicrobial agents eli-
gible for substitution at the same dose and frequency.
Nevertheless, we cannot exclude the possibility that
these additional interventions may have had an impact
on antimicrobial use and cost.
Similar to other recent reports from the United States,
we observed more than one antimicrobial agent was pre-
scribed for 46% of audited records. In a retrospective
study of adult, nonpsychiatric inpatients prescribed two or
more consecutive days of antibiotic therapy at a tertiary
care hospital in New York, two or more antibiotic agents
were employed for 63% percent of 10,154 hospitalizations
[22]. In an observational study of adult inpatients pre-
scribed fluoroquinolones at a tertiary care hospital in
Ohio, 56% of 227 regimens combined fluoroquinolones
with antibiotic agents from other classes [23].
We observed a pulmonary source of infection was an
indication for antimicrobial therapy in 47% of audited
records. In addition, a fluoroquinolone, levofloxacin, was
prescribed in 56% of audited records and accounted for
approximately 30% of overall antibiotic consumption on
the medical-surgical service during both the baseline
and intervention periods. We speculate that these find-
ings may in part be related to antibiotic choices in a
pneumonia order set designed to align with the Centers
for Medicaid and Medicare Services National Inpatient
Quality Measure PN-6, “Initial Antibiotic Selection for
Community-Acquired Pneumonia (CAP) in Immuno-
competent Patients” [24].
Discontinuation of all antimicrobial therapy accounted
for 36% (85/234) of audited records with implemented
recommendations. The observed reductions in the use
of levofloxacin, and of antimicrobials overall, would
likely not have been realized if we had chosen a core
Table 4 Antimicrobial use and cost during baseline and intervention periods of an antimicrobial stewardship program
Variable DDD per 100 Admissions DDD per 1000 Patient-days
Baseline Intervention Pa Baseline Intervention Pa
By category
Antibacterials 401.8 318.9 .009 1028 878.7 .011
Antifungals 23.1 13.2 .035 59.1 36.5 .047
Antivirals 7.5 5.2 .375 21.3 14.2 .257
All agents 432.4 337.3 .006 1109 929.4 .013
By selected class
Antipseudomonal carbapenemsb 13.8 4.4 .047 35.0 12.4 .047
Cephalosporins 42.2 49.2 .188 108.7 135.7 .030
Echinocandins 4.7 3.2 .975 11.3 8.7 .924
Fluoroquinolones 123.1 100.8 .011 314.2 279.2 .071
By selected agent
Ampicillin-sulbactam 17.6 16.1 .830 46.8 43.9 .878
Cefazolin 20.8 26.9 .013 53.7 74.9 .004
Ceftriaxone 13.2 14.5 .603 34.3 39.8 .312
Cefepime 0.5 1.9 .217 1.3 5.0 .171
Clindamycin 22.5 12.7 .004 57.4 34.8 .009
Daptomycin 2.0 0.7 .913 5.1 2.1 .855
Ertapenem 14.2 12.4 .878 35.6 34.0 .830
Fluconazole 17.6 9.8 .105 46.1 27.2 .284
Levofloxacin 122.0 97.1 .006 311.2 269.2 .030
Linezolid 4.5 0.5 .017 11.3 1.6 .020
Metronidazole 21.7 16.9 .105 55.5 46.1 .257
Nafcillin 3.0 0.3 .370 7.3 0.9 .370
Piperacillin-tazobactam 32.0 30.8 .783 80.7 84.7 .736
Tigecycline 0.2 0.2 .702 0.5 0.4 .702
Trimethoprim-sulfamethoxazole 25.6 3.9 .016 65.0 10.8 .017
Vancomycin 44.8 42.7 .783 115.2 116.2 .976
US$ per Admission US$ per Patient-day
Baseline Intervention Pa Baseline Intervention Pa
By category
Antibacterials 79.8 54.7 .025 20.2 15.1 .040
All agents 87.0 59.4 .013 22.0 16.4 .022
NOTE:
Data are means of monthly medical-surgical service antimicrobial use and cost.
a - The Mann–Whitney U test.
b - Imipenem and meropenem (doripenem was not used). A formulary change (and auto-substitution policy) from meropenem to imipenem was implemented
during the intervention period.
Abbreviations: DDD, defined daily doses (World Health Organization Center for Drug Statistics Methodology).
Storey et al. Antimicrobial Resistance and Infection Control 2012, 1:32 Page 6 of 8
http://www.aricjournal.com/content/1/1/32strategy of antibiotic restriction focused on one or more
high cost agent(s). Although inexpensive compared to
other antimicrobials and available for oral administra-
tion, fluoroquinolones have been associated with both
methicillin-resistant S. aureus and CDI in hospitals
[25,26]. Receipt of fluoroquinolones and all antibiotics
have also been shown to be independent risk factors forcarbapenem-resistant K. pneumoniae acquisition among
hospitalized adults [27].
Measurement of changes in antimicrobial resistance
patterns associated with antimicrobial stewardship has
been recommended as a potential outcome measure for
ASPs [9]. In the current report, small numbers of unique
clinical isolates precluded a meaningful assessment of
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switch from enzyme immunoassay detection of toxins to
a polymerase chain reaction assay in month 3 (November
2009) of the 16-month ASP intervention period likely
confounded comparison of healthcare-facility-onset CDI
rates. (A recent report demonstrated significant increases
and an approximate doubling of the prevalence of posi-
tive laboratory tests for CDI and the CDI rate after a
similar switch in detection methods [28]). Also, factors
other than antibiotic use may affect CDI, and we were
unable to draw any conclusions about the statistically
unchanged CDI rates between the periods [29].
Conclusions
In conclusion, an effective ASP was implemented at a
100-bed community hospital. Importantly, there were
significant reductions in overall antimicrobial use. More
focus is needed on antimicrobial stewardship strategies,
measures and resources in this healthcare setting.
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